CD8A and neoplasm: Generally, the most known immunomodulatory effects are based on US‐induced targeted tumor‐cell ICD, accompanied by the release of tumor‐associated antigens, which in turn promotes DCs maturation and further activates effector cells, including CD8+ CTLs and NK cells.